[18 F]Fluorodeoxyglucose PET for Interventional Oncology in Liver Malignancy

• Published in: PET clinics Vol. 9; no. 4; pp. 469 - 495
• Main Authors: Samim, Morsal, MD, El-Haddad, Ghassan E., MD, PhD, Molenaar, Izaak Quintes, MD, PhD, Prevoo, Warner, MD, van den Bosch, Maurice A.A.J., MD, PhD, Alavi, Abass, MD, PhD, DSc, Lam, Marnix G.E.H., MD, PhD
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01-10-2014
• Subjects: Chemoembolization; FDG-PET; Fluorodeoxyglucose F18; Humans; Imaging; Interventional oncology; Liver; Liver Neoplasms - diagnostic imaging; Liver Neoplasms - pathology; Liver Neoplasms - therapy; Multimodal Imaging; Neoplasm Recurrence, Local - diagnostic imaging; Neoplasm Staging; Positron-Emission Tomography; Radioembolization; Radiofrequency ablation; Radiology; Radiopharmaceuticals; Staging; Tomography, X-Ray Computed; FDG-PET; Interventional oncology; Staging; Liver; Imaging; Radiofrequency ablation; Radioembolization; Chemoembolization
• ISSN: 1556-8598; 1879-9809
• DOI: 10.1016/j.cpet.2014.07.004

[18 F]Fluorodeoxyglucose (FDG) PET is a functional imaging tool that provides metabolic information, which has the potential to detect a lesion before it becomes anatomically apparent. This ability constitutes a strong argument for using FDG-PET/computed tomography (CT) in the management of oncology patients. Many studies have investigated the accuracy of FDG-PET or FDG-PET/CT for these purposes, but with small sample sizes based on retrospective cohorts. This article provides an overview of the role of FDG-PET or FDG-PET/CT in patients with liver malignancies treated by means of surgical resection, ablative therapy, chemoembolization, radioembolization, and brachytherapy, all being liver-directed oncologic interventions.